Skip to content
stoqly

Charles River Laboratories

CRL NYSE Life Sciences Tools & Services Financials FY2016–FY2025

Charles River Laboratories' revenue fell 0.8% to $4.0 billion in fiscal 2025. Its operating margin was 0.6%, down from 5.6% a year earlier. Free cash flow was $518 million, up 3.4%. It paid out $361 million in dividends and buybacks, 70% of free cash flow. The diluted share count fell 4.0%.

Last close · Oct 23, 2026

$345.37

1.7%
Value it Compare
Revenue Total sales reported in the income statement.
$4.0B
0.9% vs prior year
Operating margin Operating income as a share of revenue.
0.6%
5.0 pts
Net income Profit after all expenses, interest and tax.
−$144M
750.0%
Free cash flow Cash from operations minus capital spending.
$518M
3.4%
Return on capital After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
0.4%
1.6 pts
Market cap Last close times the latest diluted share count, so it is approximate.
$16.6B
Oct 23 close
P/E Last close divided by diluted earnings per share over the last four quarters.
—

What Charles River Laboratories does

No business description yet.

Legal name
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Fiscal year ends
December 27, 2025
Latest annual report
—
Accession · CIK
0001100682-26-000022
0001100682

Revenue and margins

Charles River Laboratories had $4.0B of revenue in fiscal 2025, down 0.9% on the year before.

Revenue
Revenue
Margins, % of revenue
Gross Operating Net FCF
Margins, % of revenue
Gross Operating Net FCF

Net income and earnings per share

Loss periods are shown in red.

Net income
Net income
Diluted EPS
Diluted EPS

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

Return on capital, equity and assets (annual)
Return on capital Return on equity Return on assets

Cash flow

Free cash flow was $518M in fiscal 2025, 12.9% of revenue. Cash from operations minus capital spending.

Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations Capital spending
Cash from operations vs capital spending
Cash from operations Capital spending

Dividends, buybacks and share count

Charles River Laboratories returned $361M to shareholders in fiscal 2025, 70% of free cash flow. The diluted share count fell 4.0%.

Dividends and buybacks
Dividends Buybacks
Dividends and buybacks
Dividends Buybacks
Diluted shares outstanding (annual)

Value Charles River Laboratories yourself

Change the assumptions and see what they imply per share. These are models, not forecasts or price targets — the answer depends entirely on what you put in.

Discounted cash flow

Value per share

—

Adds net cash of −$1.9B and divides by 49.6M diluted shares. Ten years of cash flows plus a terminal value, discounted to today.

Balance sheet

Cash, debt and the ratios that show how comfortably Charles River Laboratories can carry it.

Cash vs debt (incl. leases)
Cash Debt
Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments $242M$234M$277M$195M$214M
Debt incl. finance leases $2.7B$2.7B$2.7B$2.2B$2.1B
Net debt / EBITDA 2.8x2.6x2.6x3.5x4.5x
Debt / equity 1.1x0.9x0.7x0.7x0.7x
Interest coverage 8.0x11.0x4.5x1.8x0.2x
Current ratio 1.2x1.3x1.5x1.4x1.3x
Quick ratio 1.0x1.1x1.2x1.1x1.0x
Total assets $7.0B$7.6B$8.2B$7.5B$7.1B
Total liabilities $4.4B$4.6B$4.5B$4.0B$3.9B
Shareholders' equity $2.5B$3.0B$3.6B$3.5B$3.2B
Net debt (− = net cash) $2.4B$2.5B$2.4B$2.0B$1.9B

Insider trades

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.

Bought, 12 months

$0.0M

1 insider

Sold, 12 months

$42.9M

6 insiders

Of sales under plans

93%

$39.9M

DateInsiderTradeSharesPriceValueFiling
Oct 5, 2026 Shannon M ParisottoCevp, Disc & Safety Assessment Sold plan 981 $308.44 $0.3M Form 4
Sep 30, 2026 Glenn ColemanEVP & Chief Financial Officer Bought 10 $297.43 $0.0M Form 4
Aug 25, 2026 James C FosterDirector Sold plan 33,561 $300.00 $10.1M Form 4
Aug 19, 2026 Shannon M ParisottoCevp, Disc & Safety Assessment Sold plan 2,039 $294.12 $0.6M Form 4
Aug 18, 2026 Nancy C AndrewsDirector Sold 573 $285.24 $0.2M Form 4
Aug 11, 2026 Birgit GirshickChief Executive Officer, Director Sold plan 6,500 $279.90 $1.8M Form 4
Aug 11, 2026 Shannon M ParisottoCevp, Disc & Safety Assessment Sold plan 3,714 $279.66 $1.0M Form 4
Aug 10, 2026 James C FosterDirector Sold plan 28,733 $275.00 $7.9M Form 4
Aug 6, 2026 Michael Gunnar KnellSVP, Finance and CAO Sold 6,645 $260.38 $1.7M Form 4
Aug 6, 2026 Victoria L CreamerEVP & Chief People Officer Sold 4,179 $259.16 $1.1M Form 4
Aug 5, 2026 Shannon M ParisottoCevp, Disc & Safety Assessment Sold plan 5,046 $263.00 $1.3M Form 4
Jun 29, 2026 James C FosterDirector Sold plan 75,000 $225.00 $16.9M Form 4

Piotroski F-score

Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.

TestFY23FY24FY25
Net income is positive ✓ ✓ ✕
Cash from operations is positive ✓ ✓ ✓
Return on assets rose ✕ ✕ ✕
Cash from operations exceeds net income ✓ ✓ ✓
Debt fell relative to assets ✓ ✓ ✕
Current ratio rose ✓ ✕ ✕
Share count didn't rise ✕ ✕ ✓
Gross margin rose — — —
Revenue rose relative to assets ✕ ✕ ✓
F-score 5 / 84 / 84 / 8
Accruals ratio −2.7%−9.1%−12.0%
Altman Z'' 2.532.251.81

Similar companies

Each company's latest fiscal year. Fiscal years end in different months, so periods don't line up exactly.

CompanyMarket capGrowthOp. marginFCF marginROICP/EF-score
Charles River Laboratories CRL $16.6B −0.9% 0.6% 12.9% 0.4% — 4
Mettler Toledo MTD $33.7B 4.0% — 21.1% 50.5% 37.6x 7 Compare →
Illumina ILMN $41.2B −0.7% 18.6% 21.4% 20.3% 50.3x 8 Compare →
Waters WAT $44.6B 7.0% 25.4% 17.1% 21.0% — 6 Compare →
Bio-Rad Laboratories BIO $9.9B 0.7% 1.8% 14.5% 0.5% 46.3x 5 Compare →

10 years of figures

US$ millions unless stated. Hover a ratio's name for its definition.

Download CSV
Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue $1.7B $1.9B $2.3B $2.6B $2.9B $3.5B $4.0B $4.1B $4.1B $4.0B
Gross profit $1.4B $1.6B — — — — — — — —
Operating income $238M $288M $331M $351M $433M $590M $651M $617M $227M $25.2M
Interest expense $27.7M $29.8M $63.8M $60.9M $86.4M $73.9M $59.3M $137M $126M $107M
Pretax income $223M $297M $282M $304M $447M $481M $623M $581M $93.1M −$99.5M
Income tax $66.8M $171M $54.5M $50.0M $81.8M $81.9M $130M $101M $67.8M $42.7M
Net income $155M $123M $226M $252M $364M $391M $486M $475M $22.2M −$144M
Diluted EPS $3.23 $2.54 $4.62 $5.07 $7.20 $7.60 $9.48 $9.22 $0.20 −$2.91
Diluted shares 0.05B 0.05B 0.05B 0.05B 0.05B 0.05B 0.05B 0.05B 0.05B 0.05B
Cash flow
Cash from operations $317M $318M $441M $481M $547M $761M $620M $684M $735M $738M
Capital expenditure $55.3M $82.4M $140M $141M $167M $229M $325M $319M $233M $219M
Free cash flow $262M $236M $301M $340M $380M $532M $295M $365M $502M $518M
Depreciation and amortization $127M $131M $162M $198M $235M $266M $304M $314M $362M $403M
Stock-based compensation $43.6M $44.0M $47.3M $57.3M $56.3M $71.5M $73.6M $72.0M $69.9M $71.1M
Acquisitions $649M $25.0M $825M $516M $419M $1.3B $283M $195M $5.5M $0.0M
Share buybacks $12.3M $107M $13.8M $18.1M $24.0M $40.7M $38.7M $24.2M $119M $361M
Dividends paid $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M
Dividends and buybacks $12.3M $107M $13.9M $18.1M $24.0M $40.7M $38.7M $24.2M $119M $361M
Balance sheet
Cash and short-term investments $121M $192M $196M $239M $229M $242M $234M $277M $195M $214M
Total debt $1.2B $1.1B $1.6B $1.9B $2.0B $2.7B $2.7B $2.7B $2.2B $2.1B
Finance lease liabilities $0.0M $0.0M $0.0M $30.5M $29.0M $27.2M $30.6M $28.5M $28.4M $27.9M
Current assets $657M $827M $898M $1.0B $1.2B $1.3B $1.4B $1.6B $1.4B $1.4B
Current liabilities $430M $464M $558M $710M $840M $1.0B $1.1B $1.1B $994M $1.1B
Inventory $95.8M $115M $128M $161M $186M $199M $256M $380M $279M $299M
Property and equipment, net $756M $782M $933M $1.0B $1.1B $1.3B $1.5B $1.6B $1.6B $1.7B
Total assets $2.7B $2.9B $3.9B $4.7B $5.5B $7.0B $7.6B $8.2B $7.5B $7.1B
Total liabilities $1.9B $1.9B $2.5B $3.0B $3.3B $4.4B $4.6B $4.5B $4.0B $3.9B
Shareholders' equity $837M $1.0B $1.3B $1.6B $2.1B $2.5B $3.0B $3.6B $3.5B $3.2B
Margins
Gross margin 83.5% 84.4% — — — — — — — —
Operating margin 14.1% 15.5% 14.6% 13.4% 14.8% 16.7% 16.4% 15.0% 5.6% 0.6%
EBITDA margin 21.7% 22.6% 21.8% 21.0% 22.8% 24.2% 24.0% 22.6% 14.6% 10.7%
Net margin 9.2% 6.6% 10.0% 9.6% 12.5% 11.0% 12.2% 11.5% 0.6% −3.6%
FCF margin 15.6% 12.7% 13.3% 13.0% 13.0% 15.0% 7.4% 8.9% 12.4% 12.9%
Returns
Return on capital 10.1% 7.5% 11.4% 9.8% 9.9% 11.1% 9.9% 8.9% 2.0% 0.4%
Return on capital employed 11.8% 12.1% 11.5% 9.7% 10.0% 11.1% 10.4% 9.0% 3.3% 0.4%
Return on equity 19.7% 13.1% 19.2% 17.1% 19.4% 16.8% 17.7% 14.4% 0.6% −4.4%
Return on assets 6.5% 4.4% 6.7% 5.9% 7.2% 6.3% 6.7% 6.0% 0.3% −2.0%
Growth
Revenue growth 23.3% 10.5% 22.0% 15.7% 11.6% 21.1% 12.3% 3.9% −1.9% −0.9%
Net income growth 3.7% −20.3% 83.5% 11.3% 44.6% 7.3% 24.4% −2.4% −95.3% −750.1%
EPS growth 3.2% −21.4% 81.9% 9.7% 42.0% 5.6% 24.7% −2.7% −97.8% −1,555.0%
FCF growth 7.4% −9.9% 27.8% 13.1% 11.6% 40.0% −44.6% 23.9% 37.3% 3.4%
Share count change 0.7% 1.3% 0.9% 1.4% 1.9% 1.6% −0.2% 0.3% 0.3% −4.0%
Financial health
Net debt / EBITDA 2.9x 2.1x 2.9x 3.0x 2.6x 2.8x 2.6x 2.6x 3.5x 4.5x
Debt / equity 1.4x 1.0x 1.2x 1.2x 0.9x 1.1x 0.9x 0.7x 0.7x 0.7x
Interest coverage 8.6x 9.7x 5.2x 5.8x 5.0x 8.0x 11.0x 4.5x 1.8x 0.2x
Current ratio 1.5x 1.8x 1.6x 1.4x 1.4x 1.2x 1.3x 1.5x 1.4x 1.3x
Quick ratio 1.3x 1.5x 1.4x 1.2x 1.2x 1.0x 1.1x 1.2x 1.1x 1.0x
Capital allocation
Capex / revenue 3.3% 4.4% 6.2% 5.4% 5.7% 6.5% 8.2% 7.7% 5.8% 5.5%
Stock comp / revenue 2.6% 2.4% 2.1% 2.2% 1.9% 2.0% 1.9% 1.7% 1.7% 1.8%
Payouts / FCF 4.7% 45.4% 4.6% 5.3% 6.3% 7.7% 13.1% 6.6% 23.8% 69.6%
Quality scores
Piotroski F-score 5.0 6.0 5.0 4.0 5.0 4.0 6.0 5.0 4.0 4.0
Altman Z'' 1.8 2.4 1.7 1.7 2.0 1.9 2.2 2.5 2.3 1.8
Accruals ratio −6.8% −6.9% −6.3% −5.4% −3.6% −5.9% −1.8% −2.7% −9.1% −12.0%

Source: SEC EDGAR XBRL filings (CIK 0001100682). Data updated October 9, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.

↑ ↓ to move · ↵ to open